Literature DB >> 20501981

Factor V is an anticoagulant cofactor for activated protein C during inactivation of factor Va.

Thomas J Cramer1, John H Griffin, Andrew J Gale.   

Abstract

Coagulation factor V (FV) promotes inactivation of activated factor VIII (FVIIIa) by activated protein C (APC) and protein S. Loss of this APC cofactor activity is proposed to be partially responsible for the APC resistance phenotype of FV(Leiden). However, FVIIIa loses activity rapidly due to dissociation of the A2 domain, and this may be the primary mechanism of FVIIIa inactivation. APC/protein S also readily inactivates activated FV (FVa). We therefore hypothesized that FV can function as an anticoagulant cofactor for APC/protein S in the inactivation of FVa. FV was titrated into FV-deficient plasma, and the APC sensitivity ratio (APCsr; a measure of APC activity) was measured in a clotting assay that was not sensitive to FVIII. Our results showed an increase in APCsr as the FV concentration increased, suggesting an anticoagulant function for FV in this assay. FV(Leiden) showed APC resistance with an APCsr of 1.0. Therefore, under our experimental conditions, FV acted as an anticoagulant cofactor for APC in the inactivation of FVa.
Copyright © 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20501981      PMCID: PMC2974842          DOI: 10.1159/000315141

Source DB:  PubMed          Journal:  Pathophysiol Haemost Thromb        ISSN: 1424-8832


  26 in total

1.  Activated protein C resistance caused by Arg506Gln mutation in factor Va.

Authors:  J S Greengard; X Sun; X Xu; J A Fernandez; J H Griffin; B Evatt
Journal:  Lancet       Date:  1994-05-28       Impact factor: 79.321

2.  Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V.

Authors:  B Dahlbäck; B Hildebrand
Journal:  Proc Natl Acad Sci U S A       Date:  1994-02-15       Impact factor: 11.205

3.  Radioimmunoassay of factor V in human plasma and platelets.

Authors:  P B Tracy; L L Eide; E J Bowie; K G Mann
Journal:  Blood       Date:  1982-07       Impact factor: 22.113

4.  Impaired APC cofactor activity of factor V plays a major role in the APC resistance associated with the factor V Leiden (R506Q) and R2 (H1299R) mutations.

Authors:  Elisabetta Castoldi; Jeroen M Brugge; Gerry A F Nicolaes; Domenico Girelli; Guido Tans; Jan Rosing
Journal:  Blood       Date:  2004-02-19       Impact factor: 22.113

5.  Mutation in blood coagulation factor V associated with resistance to activated protein C.

Authors:  R M Bertina; B P Koeleman; T Koster; F R Rosendaal; R J Dirven; H de Ronde; P A van der Velden; P H Reitsma
Journal:  Nature       Date:  1994-05-05       Impact factor: 49.962

6.  Structural basis for the decreased procoagulant activity of human factor VIII compared to the porcine homolog.

Authors:  P Lollar; E T Parker
Journal:  J Biol Chem       Date:  1991-07-05       Impact factor: 5.157

7.  Identification of a sequence of human activated protein C (residues 390-404) essential for its anticoagulant activity.

Authors:  R M Mesters; R A Houghten; J H Griffin
Journal:  J Biol Chem       Date:  1991-12-25       Impact factor: 5.157

8.  Improved vectors for stable expression of foreign genes in mammalian cells by use of the untranslated leader sequence from EMC virus.

Authors:  R J Kaufman; M V Davies; L C Wasley; D Michnick
Journal:  Nucleic Acids Res       Date:  1991-08-25       Impact factor: 16.971

9.  An engineered interdomain disulfide bond stabilizes human blood coagulation factor VIIIa.

Authors:  A J Gale; J-L Pellequer
Journal:  J Thromb Haemost       Date:  2003-09       Impact factor: 5.824

10.  Inhibition of the anticoagulant activity of protein S by prothrombin.

Authors:  C A Mitchell; S M Jane; H H Salem
Journal:  J Clin Invest       Date:  1988-12       Impact factor: 14.808

View more
  12 in total

Review 1.  Protein C anticoagulant and cytoprotective pathways.

Authors:  John H Griffin; Berislav V Zlokovic; Laurent O Mosnier
Journal:  Int J Hematol       Date:  2012-04-05       Impact factor: 2.490

Review 2.  Continuing education course #2: current understanding of hemostasis.

Authors:  Andrew J Gale
Journal:  Toxicol Pathol       Date:  2010-11-30       Impact factor: 1.902

3.  Function of the activated protein C (APC) autolysis loop in activated FVIII inactivation.

Authors:  Thomas J Cramer; Andrew J Gale
Journal:  Br J Haematol       Date:  2011-04-04       Impact factor: 6.998

4.  Safety, Stability and Pharmacokinetic Properties of (super)Factor Va, a Novel Engineered Coagulation Factor V for Treatment of Severe Bleeding.

Authors:  Andrew J Gale; Vikas Bhat; Jean-Luc Pellequer; John H Griffin; Laurent O Mosnier; Annette Von Drygalski
Journal:  Pharm Res       Date:  2016-03-09       Impact factor: 4.200

5.  Improved hemostasis in hemophilia mice by means of an engineered factor Va mutant.

Authors:  A von Drygalski; T J Cramer; V Bhat; J H Griffin; A J Gale; L O Mosnier
Journal:  J Thromb Haemost       Date:  2014       Impact factor: 5.824

6.  Plasma protein S residues 37-50 mediate its binding to factor Va and inhibition of blood coagulation.

Authors:  Mary J Heeb; Rolf M Mesters; José A Fernández; Tilman M Hackeng; Ryon K Nakasone; John H Griffin
Journal:  Thromb Haemost       Date:  2013-05-23       Impact factor: 5.249

7.  Reduced Prothrombinase Inhibition by Tissue Factor Pathway Inhibitor Contributes to the Factor V Leiden Hypercoagulable State.

Authors:  Jeremy P Wood; Lisa M Baumann Kreuziger; Paul E R Ellery; Susan A Maroney; Alan E Mast
Journal:  Blood Adv       Date:  2017-02-14

8.  Comparative response of platelet fV and plasma fV to activated protein C and relevance to a model of acute traumatic coagulopathy.

Authors:  James E Campbell; Michael Adam Meledeo; Andrew P Cap
Journal:  PLoS One       Date:  2014-06-12       Impact factor: 3.240

9.  An engineered factor Va prevents bleeding induced by anticoagulant wt activated protein C.

Authors:  Annette von Drygalski; Vikas Bhat; Andrew J Gale; Laurent Burnier; Thomas J Cramer; John H Griffin; Laurent O Mosnier
Journal:  PLoS One       Date:  2014-08-15       Impact factor: 3.240

10.  COVID-19, Low-Molecular-Weight Heparin, and Hemodialysis.

Authors:  Alessandra F Perna; Giovanna Capolongo; Francesco Trepiccione; Mariadelina Simeoni; Miriam Zacchia; Diego Ingrosso
Journal:  Kidney Blood Press Res       Date:  2020-05-25       Impact factor: 2.687

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.